조현병 환자에서 아미설프라이드의 치료반응과 도파민 D3 수용체 유전자다형성의 연관성 = Association Study between Treatment Response of Amisulpride and Dopamine D3 Receptor Gene Polymorphisms

다국어 초록 (Multilingual Abstract)

Objectives The aim of this study is to evaluate the association between rs6280 and rs905568 genetic polymorphism of DRD3 gene and the treatment response of amisulpride. Methods After six weeks treatment of amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S). The genotyping for rs6280 and rs905568 was performed using TaqMan single nucleotide polymorphism (SNP) genotyping assay. Results There was no significant difference in the frequency of genotype and allele of rs6280 between the responders and non-responders based on the total, positive, and general score of PANSS and CGI-S score. However, there was a significant association between this SNP and treatment response in the negative score of PANSS (${\chi}^2=5.23$, p = 0.022). There was no significant association between rs905568 and the response in positive, negative, general, and total PANSS score and CGI-S score. Conclusions This is the first positive association study between DRD3 gene and the treatment response of negative symptoms to amisulpride in Korean schizophrenia patients. A larger scale research on more SNP of the DRD3 gene will make a progress in the study of pharmacogenetics on the treatment response of the amisulpride.

참고문헌 (Reference)

1 김희철, "한국인 정신분열병 환자에서 항정신병 약물에 의한 체중 증가와 도파민 D2, D3 및 D4 수용체 유전자 다형성" 대한정신약물학회 18 (18): 299-307, 2007

2 Sokoloff P, "The third dopamine receptor (D3) as a novel target for antipsychotics" 43 : 659-666, 1992

3 Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia" 13 : 261-276, 1987

4 Mortimer A, "SOLIANOL Sudy Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia" 19 : 63-69, 2004

5 Lundstrom K, "Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system" 225 : 1068-1072, 1996

6 Sokoloff P, "Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics" 347 : 146-151, 1990

7 Colonna L, "Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group" 15 : 13-22, 2000

8 MÖller HJ, "Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group" 132 : 396-401, 1997

9 Zai CC, "Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia" 19 : 317-328, 2009

10 Xuan J, "Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study" 33 : 305-311, 2008

11 Chen SF, "Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors" 33 : 470-474, 2009

12 Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial" 371 : 1085-1097, 2008

13 Hwang R, "Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant" 10 : 200-218, 2010

14 Guy W, "ECDEU Assessment Manual for Psychopharmacology"

15 JÖnsson EG, "Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis" 13 : 1-12, 2003

16 Joyce JN, "Dopamine D3 receptor antagonists as therapeutic agents" 10 : 917-925, 2005

17 Lane HY, "Dopamine D3 receptor Ser9Gly polymorphism and risperidone response" 25 : 6-11, 2005

18 American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" American Psychiatric Publishing, Inc. 2000

19 Kim B, "Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting" 23 : 61-67, 2008

20 Puech A, "Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group" 98 : 65-72, 1998

21 Leucht S, "Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials" 159 : 180-190, 2002

22 Peuskens J, "Amisul- pride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group" 88 : 107-117, 1999

23 Shaikh S, "Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia" 97 : 714-719, 1996

24 Jeanneteau F, "A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor" 103 : 10753-10758, 2006